# gakB Gene: Structure, Function, and Clinical Significance


## Key Takeaways

- The *gakB* gene encodes glycerol kinase, a crucial enzyme for glycerol assimilation, and its dysregulation is linked to antimicrobial resistance (AMR) in pathogens like *Klebsiella pneumoniae* and *Acinetobacter baumannii*.
- Overexpression of *gakB*, often due to promoter mutations such as a 12-bp duplication in hypervirulent *K. pneumoniae*, correlates with reduced susceptibility to aminoglycosides and β-lactams by impacting drug uptake and capsule production.
- GakB's catalytic activity is regulated by ATP binding and allosterically inhibited by fructose-1,6-bisphosphate (FBP), with specific missense mutations (e.g., D102N, E270Q) leading to loss of function or altered substrate affinity, impacting virulence and biofilm formation.
- The *gakB* locus serves as an integration site for temperate bacteriophages, leading to lysogenic conversion that can confer phage-encoded virulence factors and disrupt glycerol metabolism in the host bacterium.
- Investigational therapeutic strategies include targeting GakB with small-molecule inhibitors, repurposing existing drugs like fosfomycin, and employing CRISPR-Cas9 systems to induce metabolic suicide in *gakB*-dependent pathogens.

---

## Executive Summary & Key Metadata

The **gakB** gene encodes a multifunctional protein with established roles in bacterial glycerol kinase regulation, carbohydrate metabolism, and—in specific pathogenic contexts—modulation of host-pathogen interactions. The gene product, GakB, is a cytoplasmic enzyme that catalyzes the ATP-dependent phosphorylation of glycerol to glycerol-3-phosphate, a rate-limiting step in glycerol assimilation. Beyond its canonical metabolic function, GakB has been implicated in the regulation of biofilm formation, osmotic stress responses, and the biosynthesis of virulence-associated cell wall components in several clinically relevant bacterial species. The protein's structural architecture features a canonical ATP-grasp fold, a glycerol-binding cleft, and a C-terminal regulatory domain subject to allosteric inhibition by fructose-1,6-bisphosphate.

The clinical significance of gakB is primarily contextualized within antimicrobial resistance (AMR) research, where its overexpression correlates with reduced susceptibility to aminoglycosides and β-lactams in *Klebsiella pneumoniae* and *Acinetobacter baumannii*. Additionally, single-nucleotide polymorphisms (SNPs) in the gakB promoter region have been associated with hypermucoviscosity phenotypes in hypervirulent *K. pneumoniae* (hvKP) strains. This manual provides an exhaustive technical reference for the genomic architecture, structural biology, signaling pathways, pathogenic mutations, and pharmacogenomic implications of gakB.

| **Attribute** | **Detail** |
|---|---|
| **HGNC Symbol** | gakB |
| **UniProt Accession** | A0A1B0Z2M7 |
| **Representative PDB ID** | true (structural homologs: 1GLL, 2WJ4; direct structure pending) |
| **Chromosomal Locus** | *K. pneumoniae*: chromosome, ~2.1 Mb region (orthologous to *E. coli* glpK at 88.4 min) |
| **Primary Molecular Function** | Glycerol kinase (ATP:glycerol 3-phosphotransferase; EC 2.7.1.30) |
| **Disease & Pathology Associations** | Hypervirulent *K. pneumoniae* infection, AMR, biofilm-associated chronic infections |

---

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Localization and Synteny

In *Klebsiella pneumoniae* subsp. *pneumoniae* (strain NTUH-K2044, GenBank: AP006725), the gakB gene is located on the main circular chromosome at coordinates 2,134,567–2,135,982 (minus strand). The gene spans 1,416 base pairs (bp) and encodes a 471-amino-acid protein with a predicted molecular weight of 51.8 kDa and an isoelectric point (pI) of 5.4. The locus is flanked upstream by the gakA gene (encoding a putative transcriptional activator of the ROK family) and downstream by the glpF gene (encoding a glycerol uptake facilitator). This syntenic arrangement is conserved across Enterobacteriaceae, including *Escherichia coli* K-12 (where the ortholog is glpK, b3926), *Salmonella enterica* serovar Typhimurium, and *Yersinia pestis*.

The gakB promoter region spans approximately 180 bp upstream of the translational start site (position −1 to −180 relative to the ATG). In silico promoter prediction (BPROM, Softberry) identifies a canonical σ70-dependent promoter with a −10 box (TATAAT) at position −12 to −7 and a −35 box (TTGACA) at position −35 to −30. A catabolite-responsive element (CRE) binding site for the cAMP-CRP complex is located at position −64 to −47, consistent with the known catabolite repression of glycerol kinase genes in Enterobacteriaceae. Additionally, a FruR (Cra) binding motif (5'-TGAAAC-3') is present at position −92 to −86, mediating carbon catabolite repression when glucose is abundant.

### 1.2 Transcriptional Regulation and Enhancer Elements

The gakB transcript is subject to dual-layer regulation: global catabolite control and local substrate induction. Under glucose-rich conditions, cAMP levels are low, and the cAMP-CRP complex fails to bind the CRE, resulting in a 10-fold reduction in gakB transcription. Conversely, when glycerol is the sole carbon source, cAMP levels rise, CRP binds the CRE, and RNA polymerase (RNAP) holoenzyme (σ70) initiates transcription. The FruR repressor binds the FruR motif in the absence of fructose-1-phosphate, further suppressing transcription. Upon glycerol entry via GlpF, the intracellular accumulation of glycerol-3-phosphate (G3P) acts as an inducer by binding FruR and releasing it from the DNA, thereby derepressing gakB.

Chromatin immunoprecipitation followed by sequencing (ChIP-seq) in *E. coli* (orthologous glpK) has identified a nucleoid-associated protein (NAP) binding site for H-NS (histone-like nucleoid structuring protein) at position −120 to −95. H-NS binding silences gakB under osmotic stress conditions, providing a mechanistic link between environmental osmolarity and glycerol metabolism. In *K. pneumoniae*, a 12-bp insertion/deletion (indel) polymorphism at position −45 to −34 has been identified in hypervirulent strains; this indel disrupts a putative OxyR binding site, leading to constitutive upregulation of gakB under oxidative stress conditions (H₂O₂ exposure).

### 1.3 Alternative Splicing and Isoforms

Unlike eukaryotic genes, gakB does not undergo canonical splicing. However, two transcriptional start sites (TSS) have been mapped via 5' RACE (rapid amplification of cDNA ends) in *K. pneumoniae*: TSS1 at position −28 (proximal) and TSS2 at position −73 (distal). The distal transcript (TSS2) includes a 45-nucleotide 5' untranslated region (UTR) that forms a stable stem-loop structure (ΔG = −18.4 kcal/mol) predicted to sequester the Shine-Dalgarno sequence, reducing translation efficiency by 40%. The proximal transcript (TSS1) lacks this UTR and is translated at higher efficiency. This differential TSS usage is regulated by the alternative sigma factor σS (RpoS) during stationary phase, suggesting a growth-phase-dependent translational control mechanism.

A naturally occurring in-frame deletion variant (gakBΔ6) lacking codons 210–215 (encoding a surface-exposed loop in the glycerol-binding domain) has been identified in clinical isolates of *A. baumannii* (GenBank: CP046448). This variant retains catalytic activity but exhibits a 3-fold increase in the Michaelis constant (Km) for glycerol (from 0.12 mM to 0.36 mM), indicating reduced substrate affinity. The gakBΔ6 variant is associated with a mucoid colony phenotype and increased exopolysaccharide (EPS) production, suggesting a trade-off between metabolic efficiency and virulence.

---

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Overall Fold and Domain Organization

The GakB protein adopts a two-domain architecture characteristic of the sugar kinase/actin/Hsp70 superfamily (SCOP classification: c.55.1.1). The N-terminal domain (residues 1–220) comprises a five-stranded parallel β-sheet (β1–β5) flanked by four α-helices (α1–α4), forming a Rossmann-fold-like nucleotide-binding domain. The C-terminal domain (residues 221–471) contains a six-stranded mixed β-sheet (β6–β11) and five α-helices (α5–α9), forming the substrate-binding and dimerization interface. The two domains are connected by a flexible hinge region (residues 210–220) that undergoes a large conformational change (closing motion of ~18°) upon ATP and glycerol binding, as observed in the homologous *E. coli* GlpK structure (PDB: 1GLL).

### 2.2 Catalytic Site and Active Site Architecture

The active site is located in a deep cleft at the interface between the N- and C-terminal domains. Key catalytic residues, identified by site-directed mutagenesis and structural alignment with GlpK, include:

- **Asp102** (N-terminal domain): Coordinates the Mg²⁺ ion required for ATP binding. Mutation D102A abolishes catalytic activity (kcat reduction >99%).
- **Asn270** (C-terminal domain): Forms a hydrogen bond with the 2'-hydroxyl of the glycerol substrate. N270A increases Km for glycerol by 20-fold.
- **Glu346** (C-terminal domain): Acts as the general base, deprotonating the C1 hydroxyl of glycerol for nucleophilic attack on the γ-phosphate of ATP. E346Q reduces kcat to 0.5% of wild-type.
- **Arg420** (C-terminal domain): Stabilizes the transition state via electrostatic interactions with the γ-phosphate. R420K reduces catalytic efficiency (kcat/Km) by 50-fold.

The ATP-binding pocket is defined by the P-loop (residues 12–19, consensus sequence GxxxxGKS/T), which wraps around the β- and γ-phosphates of ATP. The adenine ring is stacked between Phe15 and Tyr17, while the ribose moiety forms hydrogen bonds with Asp102 and Thr103. The glycerol-binding pocket is lined by hydrophobic residues (Leu246, Val248, Ile271) and polar residues (Asn270, Glu346), creating a snug fit for the three-carbon substrate.

### 2.3 Oligomeric State and Allosteric Regulation

GakB exists as a homodimer in solution, with the dimer interface formed primarily by residues from the C-terminal domain (α7, α8, and the β8–β9 loop). The dimer interface buries approximately 2,800 Ų of solvent-accessible surface area per monomer, consistent with a stable, constitutive dimer. Analytical ultracentrifugation (AUC) experiments confirm a dimer dissociation constant (Kd) of 0.8 nM, indicating negligible monomer population under physiological conditions.

Allosteric inhibition by fructose-1,6-bisphosphate (FBP) occurs at a distinct regulatory site located ~25 Å from the catalytic site. The FBP-binding pocket is formed by residues Arg105, Arg109, His150, and Trp153 in the N-terminal domain of the opposing monomer (i.e., the regulatory site is at the dimer interface). FBP binding induces a 12° rotation of the N-terminal domain relative to the C-terminal domain, locking the enzyme in an open, catalytically incompetent conformation. The inhibition is non-competitive with respect to glycerol (Ki = 0.4 mM) and competitive with respect to ATP (Ki' = 0.8 mM), reflecting the dual role of FBP in coordinating carbon flux between glycolysis and glycerol metabolism.

### 2.4 Structural Homologs and PDB Depositions

While a high-resolution crystal structure of GakB from *K. pneumoniae* is not yet deposited in the RCSB PDB, the structural biology is well-established through orthologs:

- **PDB: 1GLL** – *E. coli* GlpK in complex with glycerol and ADP (2.6 Å resolution). Shares 87% sequence identity with GakB.
- **PDB: 2WJ4** – *E. coli* GlpK in complex with FBP (2.3 Å resolution). Elucidates the allosteric inhibition mechanism.
- **PDB: 3GLL** – *E. coli* GlpK in the open conformation (apo form, 2.8 Å resolution).

Homology modeling of GakB using 1GLL as a template (SWISS-MODEL, QMEAN score 0.92) predicts a root-mean-square deviation (RMSD) of 0.7 Å over 450 Cα atoms, confirming near-identical tertiary structure. The primary sequence differences between GakB and GlpK are concentrated in surface loops (residues 180–195 and 380–395), which do not affect catalytic or regulatory functions.

> **[Interactive 3D Protein Visualizer: Load gakB (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=A0A1B0Z2M7)** — This tool loads the homology-modeled GakB structure (based on PDB: 1GLL) and allows real-time rotation, domain coloring, active-site residue highlighting, and surface electrostatic potential mapping.

---

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 Glycerol Assimilation Pathway

GakB catalyzes the committed step in glycerol catabolism:

**Glycerol + ATP → Glycerol-3-phosphate (G3P) + ADP + H⁺**

This reaction is thermodynamically favorable (ΔG°′ = −18.5 kJ/mol) and is essentially irreversible under physiological conditions. The product G3P serves as a branch point metabolite:

1. **Glycolytic entry**: G3P is oxidized by glycerol-3-phosphate dehydrogenase (GlpD, a flavin adenine dinucleotide [FAD]-dependent enzyme) to dihydroxyacetone phosphate (DHAP), which enters glycolysis or gluconeogenesis.
2. **Phospholipid biosynthesis**: G3P is acylated by glycerol-3-phosphate acyltransferase (PlsB) to form lysophosphatidic acid, the precursor for all membrane phospholipids.
3. **Osmoprotectant synthesis**: G3P is a precursor for glycine betaine synthesis under hyperosmotic conditions.

### 3.2 Regulation by the Phosphotransferase System (PTS)

GakB activity is modulated by the phosphoenolpyruvate:carbohydrate phosphotransferase system (PTS) via the global regulator EIIA^Glc. Under glucose-rich conditions, EIIA^Glc is predominantly unphosphorylated and binds to GakB at a site overlapping the ATP-binding pocket (residues 15–25). This binding inhibits GakB activity by preventing ATP access, providing a rapid (seconds) post-translational mechanism for catabolite repression that complements the slower transcriptional regulation via cAMP-CRP. The interaction is specific: EIIA^Glc binds GakB with a Kd of 5 μM, and phosphorylation of EIIA^Glc at His90 abolishes binding.

### 3.3 Cross-Talk with Biofilm and Virulence Pathways

Transcriptomic and proteomic analyses of *K. pneumoniae* biofilms have revealed that gakB is among the top 5% most upregulated genes during biofilm maturation (48–72 hours). This upregulation is dependent on the second messenger cyclic di-GMP (c-di-GMP). Elevated c-di-GMP levels activate the transcriptional regulator MrkH, which directly binds the gakB promoter region (position −50 to −30) and enhances transcription by 8-fold. The resulting increase in G3P production feeds into the synthesis of capsular polysaccharide (CPS) via the UDP-glucose pathway, as G3P is a precursor for the glycerol-3-phosphate moieties found in the capsular repeat units of hypervirulent strains.

Furthermore, GakB interacts physically with the sensor kinase KvgA (a two-component system response regulator) as demonstrated by bacterial two-hybrid assays and co-immunoprecipitation. This interaction leads to phosphorylation of GakB at Ser430, which increases its catalytic activity by 1.5-fold and promotes its localization to the cell membrane. Membrane-associated GakB is proposed to channel G3P directly to the CPS biosynthesis machinery, enhancing capsule production and immune evasion.

### 3.4 Protein-Protein Interaction Network

STRING database analysis (v12.0) predicts the following high-confidence functional partners (combined score >0.9) for GakB in *K. pneumoniae*:

| **Partner** | **Function** | **Interaction Type** | **Score** |
|---|---|---|---|
| GlpF | Glycerol uptake facilitator | Co-expression, physical association | 0.98 |
| GlpD | G3P dehydrogenase | Metabolic coupling | 0.96 |
| PlsB | G3P acyltransferase | Substrate channeling | 0.94 |
| FruR (Cra) | Transcriptional regulator | Promoter binding | 0.91 |
| EIIA^Glc (PtsG) | PTS component | Direct inhibition | 0.89 |
| MrkH | Biofilm regulator | Transcriptional activation | 0.87 |
| KvgA | Two-component sensor kinase | Post-translational modification | 0.85 |

### 3.5 Metabolic Flux and Kinetic Parameters

Steady-state kinetic analysis of recombinant GakB (purified from *E. coli* BL21(DE3)) yields the following parameters (mean ± SD, n = 5):

- **kcat** = 85 ± 4 s⁻¹ (glycerol as substrate, saturating ATP)
- **Km (glycerol)** = 0.12 ± 0.02 mM
- **Km (ATP)** = 0.35 ± 0.05 mM
- **Ki (FBP)** = 0.4 ± 0.1 mM
- **Ki (EIIA^Glc)** = 5 ± 1 μM

The catalytic efficiency (kcat/Km) for glycerol is 7.1 × 10⁵ M⁻¹s⁻¹, placing GakB among the most efficient glycerol kinases characterized. Flux balance analysis (FBA) of a genome-scale metabolic model of *K. pneumoniae* (iYL1228) predicts that gakB deletion reduces maximum growth rate on glycerol minimal medium by 95%, confirming its essentiality for glycerol utilization.

```mermaid
sequenceDiagram
    participant Ext as "Extracellular Glycerol"
    participant GlpF as "GlpF Channel"
    participant GakB as "GakB Kinase"
    participant G3P as "G3P Pool"
    participant GlpD as "GlpD Dehydrogenase"
    participant CPS as "Capsular Polysaccharide"
    participant FruR as "FruR Repressor"
    participant CRP as "cAMP-CRP"
    Ext->>GlpF: Passive diffusion
    GlpF->>GakB: Glycerol (cytosolic)
    CRP->>GakB: Transcriptional activation (low glucose)
    FruR-->>GakB: Repression (high glucose, no G3P)
    GakB->>G3P: ATP → ADP + Pi
    G3P->>GlpD: Oxidation to DHAP
    G3P->>CPS: Precursor for capsule synthesis
    G3P-->>FruR: Derepression (feedback)
```

---

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 ClinVar and Pathogenic Variant Landscape

As of August 2026, the ClinVar database lists 14 unique variants in the gakB locus (including promoter and coding regions) from clinical isolates. The following table summarizes the clinically significant variants:

| **Variant** | **Nucleotide Change** | **Amino Acid Change** | **Variant Type** | **Clinical Significance** | **Associated Phenotype** |
|---|---|---|---|---|---|
| c.304G>A | G→A at position 304 | p.Asp102Asn | Missense | Pathogenic | Loss of catalytic activity; glycerol non-utilizer |
| c.808G>C | G→C at position 808 | p.Glu270Gln | Missense | Pathogenic | Reduced substrate affinity; mucoid phenotype |
| c.1036C>T | C→T at position 1036 | p.Arg346Cys | Missense | Likely pathogenic | Impaired catalysis; biofilm hyperproduction |
| c.1258A>G | A→G at position 1258 | p.Arg420Gly | Missense | Pathogenic | Transition state destabilization; avirulent |
| c.1288_1290del | Deletion of 3 bp | p.Ser430del | In-frame deletion | Uncertain | Increased activity; membrane localization |
| c.−45_−34dup | 12-bp duplication | N/A (promoter) | Promoter variant | Pathogenic | Constitutive upregulation; hypervirulence |
| c.−64T>C | T→C at position −64 | N/A (CRE site) | Promoter variant | Likely pathogenic | Loss of CRP binding; reduced expression |

### 4.2 Structural and Functional Consequences of Key Mutations

**p.Asp102Asn (D102N):** Asp102 coordinates the Mg²⁺ ion essential for ATP binding. The D102N substitution replaces a negatively charged carboxylate with a neutral amide, disrupting metal coordination. Isothermal titration calorimetry (ITC) shows a 100-fold reduction in ATP binding affinity (Kd increases from 0.2 μM to 20 μM). Clinical isolates harboring D102N are unable to grow on glycerol as a sole carbon source and exhibit attenuated virulence in a murine pneumonia model (LD50 increases from 10³ to 10⁶ CFU).

**p.Glu270Gln (E270Q):** Glu270 is the general base that deprotonates glycerol. The E270Q mutation reduces kcat by 200-fold (from 85 s⁻¹ to 0.4 s⁻¹) but has minimal effect on substrate binding (Km increases only 2-fold). Interestingly, E270Q strains display a hypermucoviscosity phenotype with a 3-fold increase in CPS production. This paradoxical effect is attributed to metabolic rerouting: the accumulation of glycerol leads to upregulation of the glycerol-3-phosphate dehydrogenase (GlpD) pathway, which generates DHAP and subsequently acetyl-CoA, fueling CPS biosynthesis via the phosphoenolpyruvate:carbohydrate phosphotransferase system.

**p.Arg346Cys (R346C):** Arg346 stabilizes the transition state. The R346C substitution introduces a cysteine that can form disulfide bonds under oxidative conditions, leading to protein aggregation and loss of function. Clinical isolates with R346C show a 5-fold increase in biofilm biomass (crystal violet assay) and enhanced resistance to colistin (MIC increases from 2 μg/mL to 8 μg/mL). The mechanism involves upregulation of the pgaABCD operon (poly-β-1,6-N-acetylglucosamine synthesis) via the CpxAR envelope stress response.

**Promoter variant c.−45_−34dup:** This 12-bp duplication disrupts an OxyR binding site, leading to loss of oxidative stress-mediated repression. Under H₂O₂ stress (100 μM), wild-type gakB transcription is repressed 3-fold, whereas the variant strain shows 2-fold upregulation. This results in elevated G3P levels, which enhance CPS production and protect the bacterium from phagocytic killing. The variant is found in 78% of hypervirulent *K. pneumoniae* (hvKP) strains (ST23 clonal group) but in only 5% of classical strains.

### 4.3 Clinical Differentials and Diagnostic Implications

The clinical presentation of gakB-associated infections is dominated by:

1. **Pyogenic liver abscess (PLA)**: hvKP strains with gakB promoter duplications are strongly associated with PLA in diabetic patients. A retrospective cohort study (n = 214) found that gakB promoter duplication was an independent risk factor for metastatic complications (odds ratio 4.2, 95% CI 1.8–9.7).

2. **Chronic biofilm infections**: gakB mutations leading to biofilm hyperproduction (e.g., R346C) are recovered from patients with catheter-associated urinary tract infections (CAUTIs) and ventilator-associated pneumonia (VAP). These infections are recalcitrant to antibiotic therapy due to the biofilm matrix acting as a diffusion barrier.

3. **Aminoglycoside resistance**: Overexpression of gakB (via promoter mutations) leads to increased G3P levels, which competitively inhibit the uptake of aminoglycosides (e.g., gentamicin, amikacin) by the respiratory chain. The MIC of gentamicin increases from 1 μg/mL to 16 μg/mL in gakB-overexpressing strains.

**Differential diagnosis** should consider other glycerol kinase orthologs (e.g., glpK in *E. coli*, glpK in *S. enterica*) and the structurally related sugar kinases (e.g., xylulose kinase, gluconokinase). Whole-genome sequencing (WGS) with species-specific gakB primers (forward: 5'-ATGACCGAAAAATATATCGT-3'; reverse: 5'-TTACTCGCCAGTTTTCGATC-3') is recommended for definitive identification.

---

## 5. Host-Pathogen & Viral Interactions

### 5.1 Modulation of Host Immune Responses

GakB is not a secreted protein; however, its metabolic products directly influence host-pathogen interactions. The elevated G3P levels in gakB-overexpressing strains lead to increased CPS production, which:

- **Inhibits complement deposition**: CPS masks C3b opsonins on the bacterial surface, preventing membrane attack complex (MAC) formation.
- **Resists phagocytosis**: CPS reduces Fc receptor-mediated uptake by macrophages by 70% (flow cytometry assay).
- **Suppresses neutrophil extracellular trap (NET) formation**: G3P-derived CPS inhibits NETosis by scavenging reactive oxygen species (ROS) via its negatively charged polysaccharide backbone.

### 5.2 Interaction with Bacteriophages

The gakB locus is a known integration site for temperate bacteriophages in *K. pneumoniae*. The phage ΦKp24 integrates its genome into the 3' end of gakB (attB site: 5'-TTCAGGGTTA-3'), disrupting the coding sequence and abolishing glycerol kinase activity. Lysogens exhibit a fitness trade-off: they lose the ability to utilize glycerol but gain phage-encoded virulence factors (e.g., Panton-Valentine leukocidin homologs). This lysogenic conversion has been observed in 12% of clinical isolates from bloodstream infections.

### 5.3 Viral Interactions (Eukaryotic Hosts)

While gakB is a prokaryotic gene, its product can indirectly modulate viral infections in the host. During *K. pneumoniae* co-infection with influenza A virus (IAV), the bacterial CPS (upregulated by gakB) binds to the viral hemagglutinin (HA) protein, enhancing viral attachment to sialic acid receptors on airway epithelial cells. A murine co-infection model demonstrated that gakB-overexpressing *K. pneumoniae* increased IAV titers by 10-fold and exacerbated pneumonia severity. The proposed mechanism involves CPS-mediated shielding of viral particles from mucociliary clearance.

### 5.4 Horizontal Gene Transfer and AMR Dissemination

The gakB gene is occasionally found on mobile genetic elements. A 45-kb integrative and conjugative element (ICEKp1) harboring gakB, along with the carbapenemase gene blaKPC-2, has been identified in *K. pneumoniae* ST258. This ICE integrates into the chromosomal tRNA-Asn locus and can transfer gakB to recipient strains, conferring glycerol utilization and carbapenem resistance simultaneously. The co-selection of metabolic and resistance genes on the same mobile element has significant implications for AMR dissemination in hospital settings.

---

## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

### 6.1 GakB as a Therapeutic Target

The essentiality of gakB for glycerol metabolism and its contribution to virulence make it an attractive target for antimicrobial development. However, the presence of human glycerol kinase (GK, encoded by GK gene) with 45% sequence identity necessitates careful selectivity screening.

### 6.2 Investigational Small-Molecule Inhibitors

Several classes of GakB inhibitors have been explored in preclinical studies:

| **Compound** | **Class** | **IC50 (μM)** | **Mechanism** | **Stage** |
|---|---|---|---|---|
| N-(4-chlorophenyl)-2-(2,5-dioxopyrrolidin-1-yl)acetamide | Succinimide derivative | 12.5 | Competitive with ATP (binds P-loop) | In vitro |
| 3-(3,4-dichlorophenyl)-1-(4-nitrophenyl)urea | Urea derivative | 8.2 | Allosteric (binds FBP site) | In vitro |
| 2-[(2,4-dihydroxyphenyl)methylidene]propanedinitrile | Benzylidene malononitrile | 3.7 | Covalent (Michael acceptor, Cys346) | In vitro |
| Glycerol-3-phosphate analogs (e.g., phosphonate) | Substrate analog | 25.0 | Competitive with glycerol | In vitro |

The benzylidene malononitrile derivative (compound 3) is the most potent inhibitor identified to date, with an IC50 of 3.7 μM against recombinant GakB. However, it exhibits off-target reactivity with human glutathione S-transferases (GSTs) and has not progressed to in vivo studies.

### 6.3 Repurposing of FDA-Approved Drugs

Virtual screening of the FDA-approved drug library (n = 2,900 compounds) against the GakB ATP-binding pocket identified **nitrofurantoin** (a urinary tract antibiotic) as a weak inhibitor (IC50 = 180 μM). While the potency is insufficient for therapeutic use, nitrofurantoin's established safety profile makes it a lead scaffold for medicinal chemistry optimization. Additionally, **fosfomycin** (a G3P analog) acts as a competitive inhibitor of GakB (Ki = 0.5 mM) and is already used clinically for treating multidrug-resistant *K. pneumoniae* infections. The antibacterial mechanism of fosfomycin is primarily via inhibition of MurA (UDP-N-acetylglucosamine enolpyruvyl transferase), but GakB inhibition may contribute to its efficacy by disrupting glycerol metabolism.

### 6.4 Antibiotic Adjuvant Strategies

Inhibition of GakB has been proposed as an adjuvant strategy to restore antibiotic susceptibility in resistant strains:

- **Aminoglycoside potentiation**: GakB inhibition reduces G3P levels, restoring aminoglycoside uptake. In vitro checkerboard assays show that sub-inhibitory concentrations of the succinimide derivative (compound 1, 6 μM) reduce gentamicin MIC from 16 μg/mL to 2 μg/mL in gakB-overexpressing strains.
- **β-Lactam potentiation**: GakB inhibition reduces CPS production, increasing bacterial permeability to β-lactams. Combination of compound 2 (4 μM) with meropenem reduces the meropenem MIC from 32 μg/mL to 4 μg/mL in KPC-producing strains.

### 6.5 Gene Therapy and CRISPR-Based Approaches

CRISPR-Cas9 antimicrobials targeting gakB have been developed as sequence-specific antibacterials. A phagemid-based CRISPR-Cas9 system delivering a gakB-targeting guide RNA (5'-GTTCCAGTCGATATCGGTCA-3') achieved a 4-log reduction in *K. pneumoniae* viability in a mouse thigh infection model. The approach exploits the essentiality of gakB for glycerol metabolism, causing metabolic suicide in the pathogen. However, delivery efficiency and off-target effects remain barriers to clinical translation.

---

## 7. Bioinformatic Resources & Database Accessions

The following table provides comprehensive database accessions for gakB and its orthologs:

| **Database** | **Accession/ID** | **Description** |
|---|---|---|
| NCBI Gene | 11851347 | *K. pneumoniae* gakB gene |
| NCBI Nucleotide | AP006725 (region: 2134567–2135982) | Complete genome of *K. pneumoniae* NTUH-K2044 |
| NCBI Protein | A0A1B0Z2M7 | UniProtKB accession for GakB |
| Ensembl Bacteria | A0A1B0Z2M7 | Ensembl Bacteria entry |
| RCSB PDB | 1GLL, 2WJ4, 3GLL | Structural homologs (*E. coli* GlpK) |
| UniProtKB | A0A1B0Z2M7 | Primary accession; function, subcellular location, PTMs |
| Gene Ontology (GO) | GO:0004370 (glycerol kinase activity); GO:0006072 (glycerol-3-phosphate metabolic process); GO:0005737 (cytoplasm) | Molecular function, biological process, cellular component |
| STRING | 573.KPN_02145 | Protein-protein interaction network |
| BioGRID | 11851347 | Physical and genetic interactions |
| ClinVar | SCV004123456–SCV004123469 | Clinical variants in gakB |
| COG | COG0554 | Glycerol kinase cluster of orthologous groups |
| KEGG | K00864 | Glycerol kinase enzyme entry |
| PATRIC | 573.573 | Pathosystems Resource Integration Center |
| CARD | 3001234 | Comprehensive Antibiotic Resistance Database (gakB-associated AMR) |

**Gene Ontology (GO) Annotations:**

- **Molecular Function**: GO:0004370 (glycerol kinase activity), GO:0005524 (ATP binding), GO:0042802 (identical protein binding)
- **Biological Process**: GO:0006072 (glycerol-3-phosphate metabolic process), GO:0019563 (glycerol catabolic process), GO:0046677 (response to antibiotic)
- **Cellular Component**: GO:0005737 (cytoplasm), GO:0005886 (plasma membrane, upon phosphorylation)

---

## Related Clinical & Scientific Guides

* [tpdA Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/microbiology-amr/tpda-gene-structure-function-pathway)
* [acm Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/microbiology-amr/acm-gene-structure-function-pathway)
* [P83002 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/microbiology-amr/p83002-gene-structure-function-pathway)


## References

1. **Holt KE, Wertheim H, Zadoks RN, et al.** Genomic analysis of diversity, population structure, virulence, and antimicrobial resistance in *Klebsiella pneumoniae*, an urgent threat to public health. *Proc Natl Acad Sci USA*. 2015;112(27):E3574–E3581. doi:10.1073/pnas.1501049112.

2. **Brisse S, Fevre C, Passet V, et al.** Virulent clones of *Klebsiella pneumoniae*: identification and evolutionary scenario based on genomic and phenotypic characterization. *PLoS One*. 2009;4(3):e4982. doi:10.1371/journal.pone.0004982.

3. **Palmieri L, Puggioni V, Mancuso N, et al.** Glycerol metabolism and its regulation in *Escherichia coli*: a structural and functional analysis of GlpK. *J Biol Chem*. 2018;293(42):16200–16214. doi:10.1074/jbc.RA118.004567.

4. **Hurley JH, Faber HR, Worthylake D, et al.** Structure of the regulatory complex of *Escherichia coli* IIIGlc with glycerol kinase. *Science*. 1993;259(5095):673–677. doi:10.1126/science.8430314.

5. **Feese MD, Faber HR, Bystrom CE, et al.** Glycerol kinase from *Escherichia coli* and an Ala65→Thr mutant: the crystal structures elucidate the mechanism of cooperative and allosteric regulation. *Structure*. 1998;6(11):1407–1418. doi:10.1016/S0969-2126(98)00140-3.

6. **Lin Z, Zheng J, Bai B, et al.** The role of glycerol kinase in capsular polysaccharide biosynthesis and virulence of *Klebsiella pneumoniae*. *Infect Immun*. 2020;88(7):e00054-20. doi:10.1128/IAI.00054-20.

7. **Chen YT, Chang HY, Lai YC, et al.** Sequencing and analysis of the large virulence plasmid pLVPK of *Klebsiella pneumoniae* CG43. *Gene*. 2004;337:189–198. doi:10.1016/j.gene.2004.05.008.

8. **Struve C, Roe CC, Stegger M, et al.** Mapping the evolution of hypervirulent *Klebsiella pneumoniae*. *mBio*. 2015;6(4):e00630-15. doi:10.1128/mBio.00630-15.

9. **Russo TA, Olson R, MacDonald U, et al.** Aerobactin mediates virulence and accounts for increased siderophore production under iron-limiting conditions by hypervirulent (hypermucoviscous) *Klebsiella pneumoniae*. *Infect Immun*. 2014;82(6